What is the appropriate Arnuity Ellipta (fluticasone furoate) dose when switching a patient from Flovent HFA (fluticasone propionate) 220 µg twice daily?

Dose Conversion: Flovent HFA 220 mcg to Arnuity Ellipta

When switching from Flovent HFA 220 mcg twice daily (total daily dose 440 mcg) to Arnuity Ellipta, start with Arnuity Ellipta 200 mcg once daily.

Rationale for Dosing

Flovent HFA 220 mcg twice daily delivers 440 mcg/day of fluticasone propionate, which falls in the high-dose range for adults according to NAEPP guidelines (>440 mcg/day is high-dose) 1. This patient is on the threshold of high-dose inhaled corticosteroid therapy.

The key consideration is that fluticasone furoate (Arnuity Ellipta) and fluticasone propionate (Flovent HFA) are different molecules with different potencies. While both are fluticasone compounds, they are not interchangeable on a microgram-per-microgram basis 1.

Evidence-Based Conversion

Based on FDA-approved dosing and clinical trial data:

• Arnuity Ellipta 200 mcg once daily demonstrated comparable efficacy to fluticasone propionate 500 mcg twice daily (1000 mcg/day total) in 24-week trials 2
• At Week 24, mean change from baseline in trough FEV₁ was 201 mL for Arnuity Ellipta 200 mcg versus 183 mL for fluticasone propionate 500 mcg twice daily 2
• Arnuity Ellipta 200 mcg sustained lung function improvements over the full 24-hour dosing period 2

This suggests that Arnuity Ellipta 200 mcg once daily provides equivalent or slightly superior efficacy to approximately twice the daily dose of fluticasone propionate.

Dosing Algorithm

For patients on Flovent HFA 220 mcg twice daily (440 mcg/day):

1. Start Arnuity Ellipta 200 mcg once daily - This is the appropriate dose based on:

   • The patient's current medium-to-high dose ICS therapy
   • Clinical trial data showing Arnuity Ellipta 200 mcg matches or exceeds fluticasone propionate 500 mcg twice daily 2
   • FDA-approved dosing for adults with asthma requiring medium-to-high dose ICS 2

2. Consider Arnuity Ellipta 100 mcg once daily only if:

   • The patient has been well-controlled on current therapy and you're attempting step-down
   • The patient experienced systemic corticosteroid side effects on Flovent HFA 440 mcg/day

Important Clinical Considerations

Timing of administration: Arnuity Ellipta should be administered once daily in the evening for optimal efficacy, as this was the dosing schedule used in pivotal trials 3, 4.

Monitor for adequate control: Assess asthma control at 2-4 weeks after switching, as the efficacy plateau is reached within 2 weeks 5. Key parameters include:

• Trough FEV₁ measurements
• Symptom-free and rescue-free 24-hour periods
• Peak expiratory flow rates

Systemic effects: Both medications have similar systemic bioavailability profiles (approximately 12-15%) 6, but fluticasone furoate has 1.7-fold higher glucocorticoid receptor-binding affinity than fluticasone propionate 6. However, at therapeutic doses (Arnuity Ellipta 200 mcg), cortisol suppression remains minimal and not significantly different from placebo 7.

Common pitfall to avoid: Do not attempt a 1:1 microgram conversion. Fluticasone furoate 440 mcg once daily would be excessive and is not an FDA-approved dose. The maximum approved dose of Arnuity Ellipta is 200 mcg once daily for adults 2.

Device transition: Ensure proper inhaler technique education, as Arnuity Ellipta is a dry powder inhaler requiring different inhalation technique than the Flovent HFA metered-dose inhaler 2.